Metformin in patients with chronic and acute heart failure: Pharmacokinetics and polymorphisms in genes encoding membrane metformin transporter proteins

Aarhus University Hospital0 个研究点目标入组 162 人开始时间: 2016年4月27日最近更新: 2018年6月5日

试验速览

暂无简介。

•Substudy A:
•Patients with decompensated heart failure
•Increased need for diuretics as judged by the clinicians
•LVEF < 45% measured during admission or within 12 months prior to inclusion
•NYHA-class I, II, III or IV
•Ability to understand the written patient information and to give informed consent
•Diabetes Type 2 (and in metformin treatment for > 1 month)
•Stable dosage of metformin treatment for at least 1 week prior to examination
•Substudy B:
•Patients with heart failure
•LVEF < 45% within 12 months prior to inclusion
•NYHA-class I, II, III or IV
•Ability to understand the written patient information and to give informed consent
•Diabetes Type 2 (and in metformin treatment for > 1 month)
•Stable dosage of metformin treatment for at least 1 week prior to examination
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 80
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 82

•Substudy A:
•Severe cardiac failure, defined as
•osystolic blood pressure continuously < 85 mmHg
•osigns of tissue hypoperfusion (oliguria < 30 mL/h, altered level of consciousness, rapid deterioration of kidney function)
•oNeed for intravenous inotropic support
•Age < 18 years
•Current abuse of alcohol or drugs
•Adjustment or discontinuation of metformin dose during admission before examination
•Substudy B:
•Age < 18 years
•Current abuse of alcohol or drugs

发起方

Aarhus University Hospital